

# Ramipril and the Development of Diabetes

JAMA - Journal of the American Medical Association  
286, 1882

DOI: [10.1001/jama.286.15.1882](https://doi.org/10.1001/jama.286.15.1882)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. , 2001, 11, 474-490.		7
3	Ramipril and Risk of Diabetes. JAMA - Journal of the American Medical Association, 2002, 287, 186.	3.8	0
5	Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells. Hypertension, 2002, 40, 609-611.	1.3	259
6	The Losartan Intervention for Endpoint Reduction (LIFE) Trialâ€™Have Angiotensinâ€™Receptor Blockers Come of Age?. Journal of Clinical Hypertension, 2002, 4, 301-305.	1.0	7
7	Quinapril. Drugs, 2002, 62, 339-385.	4.9	15
8	Ramipril. Drugs, 2002, 62, 1381-1405.	4.9	56
9	Opinion and Evidence for Treatments in Endocrine Disorders. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2002, 1, 59-69.	1.8	0
10	Ramipril reduces the risk of developing diabetes in high-risk people. Evidence-based Cardiovascular Medicine, 2002, 6, 63-64.	0.0	0
12	Dysmetabolic Syndrome: Multiple Risk Factors for Premature Adult Disease in an Adolescent Girl. Pediatrics, 2002, 110, e14-e14.	1.0	22
13	Facts and Ideas from Anywhere. Baylor University Medical Center Proceedings, 2002, 15, 107-118.	0.2	0
14	National Pharmacy Cardiovascular Council Treatment Guidelines for the Management of Type 2 Diabetes Mellitus: Toward Better Patient Outcomes and New Roles for Pharmacists. Pharmacotherapy, 2002, 22, 436-444.	1.2	28
15	Addressing the Insulin Resistance Syndrome A Role for the Thiazolidinediones. Trends in Cardiovascular Medicine, 2002, 12, 354-362.	2.3	42
16	Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. Journal of Diabetes and Its Complications, 2002, 16, 401-415.	1.2	72
17	Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. Current Diabetes Reports, 2002, 2, 396-402.	1.7	16
18	Preventing diabetes by treating aspects of the metabolic syndrome. Current Diabetes Reports, 2002, 2, 416-422.	1.7	14
19	Are clinical endpoint benefits of angiotensin converting enzyme inhibitors independent of their blood pressure effects?. Current Hypertension Reports, 2002, 4, 290-297.	1.5	1
20	Angiotensin-receptor blockers: Another victory. Current Hypertension Reports, 2002, 4, 321-323.	1.5	6
21	The value of large, robust trials: the HOPE study. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2002, 19, 29-30.	0.2	1

#	ARTICLE	IF	CITATIONS
22	ACE inhibitors and diabetes: from HOPE to PROGRESS. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2002, 19, 176-179.	0.2	1
23	The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia, 2003, 46, 3-19.	2.9	1,767
25	The renin-angiotensin-aldosterone system as a target in coronary disease. Current Atherosclerosis Reports, 2003, 5, 124-130.	2.0	12
26	Epidemiology of the insulin resistance syndrome. Current Diabetes Reports, 2003, 3, 73-79.	1.7	64
27	Diagnosis, prevention, and intervention for the metabolic syndrome. American Journal of Cardiology, 2003, 92, 35-42.	0.7	157
28	Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovascular Diabetology, 2003, 2, 4.	2.7	76
30	Treating Type 2 Diabetes Mellitus: A Growing Epidemic. Mayo Clinic Proceedings, 2003, 78, 411-413.	1.4	16
31	Prevention of type 2 diabetes: data from recent trials. Primary Care - Clinics in Office Practice, 2003, 30, 511-526.	0.7	33
33	Functional Interplay Between Angiotensin II and Nitric Oxide. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 26-36.	1.1	163
34	Is There a Role for ??-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?. Drugs, 2003, 63, 933-951.	4.9	197
35	Current Management Strategies for Coexisting Diabetes Mellitus and Obesity. Drugs, 2003, 63, 1165-1184.	4.9	76
36	The prevention of type 2 diabetes – lifestyle change or pharmacotherapy? A challenge for the 21st century. Diabetes Research and Clinical Practice, 2003, 59, 165-180.	1.1	77
37	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, The, 2003, 362, 759-766.	6.3	1,752
38	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, The, 2003, 362, 777-781.	6.3	2,584
39	ACE inhibition may decrease diabetes risk by boosting the impact of bradykinin on adipocytes. Medical Hypotheses, 2003, 60, 779-783.	0.8	15
40	Can the premises of the altered homeostatic theory permit improvement in the prevention of ischemic heart disease?. Medical Hypotheses, 2003, 60, 12-25.	0.8	3
41	Metformin and vascular protection: a cardiologist's view. Diabetes and Metabolism, 2003, 29, 6S117-6S120.	1.4	9
42	Minireview: Adiposity, Inflammation, and Atherogenesis. Endocrinology, 2003, 144, 2195-2200.	1.4	684

#	ARTICLE	IF	CITATIONS
43	Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management. <i>Annals of Internal Medicine</i> , 2003, 139, 824.	2.0	122
44	Prevention and Treatment of Diabetic Nephropathy in Older Patients. <i>Drugs and Aging</i> , 2003, 20, 419-435.	1.3	2
45	Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies. <i>Diabetes</i> , 2003, 52, 2160-2167.	0.3	394
46	Spotlight on Ramipril in the Prevention of Cardiovascular Outcomes <sup>1</sup> . <i>American Journal of Cardiovascular Drugs</i> , 2003, 3, 113-116.	1.0	2
47	Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 1291-1296.	1.6	230
48	American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25-26 August 2002, Washington, DC. <i>Diabetes Care</i> , 2003, 26, 1297-1303.	4.3	66
49	Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension. <i>Hypertension</i> , 2003, 42, 76-81.	1.3	446
52	Pharmacological Agents That Directly Modulate Insulin Secretion. <i>Pharmacological Reviews</i> , 2003, 55, 105-131.	7.1	217
53	HOPE Study Impact on ACE Inhibitors Use. <i>Annals of Pharmacotherapy</i> , 2003, 37, 640-645.	0.9	12
56	Vasopeptidase Inhibitor Omapatrilat Induces Profound Insulin Sensitization and Increases Myocardial Glucose Uptake in Zucker Fatty Rats. <i>Circulation</i> , 2003, 107, 1923-1929.	1.6	58
57	Is Type 2 Diabetes Mellitus a Vascular Condition?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1715-1716.	1.1	38
58	Insulin resistance: a global epidemic in need of effective therapies. <i>European Heart Journal Supplements</i> , 2003, 5, C13-C18.	0.0	17
59	Pharmacologic Approaches to the Prevention of Type 2 Diabetes in High Risk Pediatric Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3-13.	1.8	33
60	Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. <i>European Heart Journal Supplements</i> , 2003, 5, A43-A48.	0.0	25
61	Diabetes Mellitus and Hypertension: A Mandate for Intense Treatment According to New Guidelines. <i>American Journal of Therapeutics</i> , 2003, 10, 363-369.	0.5	6
62	Cardiovascular Disease in Type 2 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2003, 163, 33.	4.3	132
63	Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. <i>Current Opinion in Cardiology</i> , 2003, 18, 479-485.	0.8	11
64	Benefits of blood pressure reduction in diabetic patients. <i>Journal of Hypertension</i> , 2003, 21, S31-S36.	0.3	11

#	ARTICLE	IF	CITATIONS
65	Diabetes and Heart Disease. <i>Cardiology in Review</i> , 2003, 11, 262-274.	0.6	28
66	The D Allele of the Angiotensin-Converting Enzyme Insertion/Deletion (I/D) Polymorphism is a Risk Factor for Type 2 Diabetes in a Population-Based Japanese Sample. <i>Endocrine Journal</i> , 2003, 50, 393-398.	0.7	42
67	1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. <i>Medical Journal of Australia</i> , 2003, 179, 526-526.	0.8	38
68	Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance?. <i>British Journal of Diabetes and Vascular Disease</i> , 2003, 3, S24-S40.	0.6	6
69	1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. <i>Medical Journal of Australia</i> , 2003, 179, 379-383.	0.8	57
70	Angiotensin-Converting Enzyme Inhibition in Stable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2058-2068.	13.9	1,036
71	The Metabolic Syndrome: What to Treat, How to Treat, What Are the Goals?. <i>The American Heart Hospital Journal</i> , 2004, 2, 191-197.	0.2	3
72	Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart. <i>Archives of Internal Medicine</i> , 2004, 164, 1737.	4.3	94
73	Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1. <i>Diabetes</i> , 2004, 53, 336-346.	0.3	375
74	Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome. <i>Circulation</i> , 2004, 110, 1507-1512.	1.6	176
75	Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1978.	3.8	548
76	Peroxisome Proliferator-Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease. <i>Circulation</i> , 2004, 109, 2197-2202.	1.6	157
78	The Metabolic Syndrome and Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2004, 59, M139-M142.	1.7	70
79	The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 245-253.	1.9	1
80	Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. <i>Journal of Hypertension</i> , 2004, 22, 1867-1868.	0.3	46
81	Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR $\gamma$ Modulating Activity. <i>Hypertension</i> , 2004, 43, 993-1002.	1.3	1,009
82	Diabetes and Hypertension: Pathogenesis, Prevention and Treatment. <i>Clinical and Experimental Hypertension</i> , 2004, 26, 621-628.	0.5	84
83	Metabolic and Inflammation Variable Clusters and Prediction of Type 2 Diabetes: Factor Analysis Using Directly Measured Insulin Sensitivity. <i>Diabetes</i> , 2004, 53, 1773-1781.	0.3	196

#	ARTICLE	IF	CITATIONS
84	Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. <i>Diabetic Medicine</i> , 2004, 21, 403-414.	1.2	67
85	The metabolic syndrome. <i>Nutrition Bulletin</i> , 2004, 29, 36-43.	0.8	76
86	ACE inhibitor and angiotensin type I receptor antagonist in combination reduce renal damage in obese Zucker rats. <i>Kidney International</i> , 2004, 65, 2343-2359.	2.6	38
87	The clinical use of angiotensin-converting enzyme inhibitors. <i>Progress in Cardiovascular Diseases</i> , 2004, 47, 116-130.	1.6	80
88	The metabolic syndrome: Diagnosis and treatment. <i>Clinical Cornerstone</i> , 2004, 6, S5-S13.	1.0	14
89	Metabolic syndrome and other factors associated with increased risk of diabetes. <i>Clinical Cornerstone</i> , 2004, 6, S14-S29.	1.0	20
90	Delaying the Onset of Type 2 Diabetes Mellitus in Patients with Prediabetes. <i>Pharmacotherapy</i> , 2004, 24, 362-371.	1.2	19
91	Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance. <i>American Journal of Cardiology</i> , 2004, 93, 27-31.	0.7	30
92	High prevalence of metabolic syndrome in Mexico. <i>Archives of Medical Research</i> , 2004, 35, 76-81.	1.5	128
93	Hypertension therapy: Mixing, matching, and meeting targets. <i>Advances in Therapy</i> , 2004, 21, 107-122.	1.3	5
94	Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. <i>Diabetologia</i> , 2004, 47, 1519-1527.	2.9	157
95	Clinical trials report. <i>Current Hypertension Reports</i> , 2004, 6, 365-368.	1.5	3
96	Clinical Trials Report. <i>Current Hypertension Reports</i> , 2004, 6, 161-163.	1.5	0
97	The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 288-297.	1.7	28
98	Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events. <i>Pharmacoeconomics</i> , 2004, 22, 955-973.	1.7	20
99	Impaired Glucose Metabolism in Patients with Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 269-280.	1.0	32
100	Relationship Between Antihypertensive Drugs and Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2004, 2, 308-314.	0.5	2
101	Papel de los inhibidores de la enzima convertora de la angiotensina en los pacientes con riesgo cardiovascular. <i>Revista Clinica Espanola</i> , 2004, 204, 592-593.	0.2	1

#	ARTICLE	IF	CITATIONS
102	New aspects in the pathogenesis of diabetic atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2293-2300.	1.2	310
103	Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. <i>Clinical Science</i> , 2004, 107, 539-557.	1.8	291
104	Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System. <i>Drugs</i> , 2004, 64, 2537-2565.	4.9	239
105	Drug Therapy in Transplant Recipients. <i>Drugs and Aging</i> , 2004, 21, 323-348.	1.3	19
106	Should the Insulin Resistance Syndrome be Treated in the Elderly?. <i>Drugs and Aging</i> , 2004, 21, 141-151.	1.3	14
107	Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 816-823.	1.1	1,151
108	Antihypertensive Therapy and Incidence of Type 2 Diabetes: A systematic review. <i>Diabetes Care</i> , 2004, 27, 247-255.	4.3	185
109	Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women. <i>Diabetes</i> , 2004, 53, 693-700.	0.3	682
110	Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. <i>Biochemical and Biophysical Research Communications</i> , 2004, 316, 114-122.	1.0	83
111	A common functional variant in the interleukin-6 gene is associated with increased body mass index in subjects with type 2 diabetes mellitus. <i>Molecular Genetics and Metabolism</i> , 2004, 82, 180-186.	0.5	58
112	Macrovascular complications of metabolic syndrome: an early intervention is imperative. <i>International Journal of Cardiology</i> , 2004, 97, 167-172.	0.8	40
113	Insulin resistance and the endothelium. <i>American Journal of Medicine</i> , 2004, 117, 109-117.	0.6	210
114	Physiology, Genetics, and Cardiovascular Disease: Focus on African Americans. <i>Journal of Clinical Hypertension</i> , 2004, 6, 11-18.	1.0	20
115	Metabolic Properties of Vasodilating $\beta^2$ Blockers: Management Considerations for Hypertensive Diabetic Patients and Patients With the Metabolic Syndrome. <i>Journal of Clinical Hypertension</i> , 2004, 6, 690-696.	1.0	20
116	Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. <i>Diabetes and Metabolism</i> , 2004, 30, 487-496.	1.4	238
117	Antihypertensive therapy and new onset diabetes. <i>Journal of Hypertension</i> , 2004, 22, 1845-1847.	0.3	59
118	Preventing Type II Diabetes Mellitus. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 406-413.	1.0	50
119	Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. <i>Current Opinion in Cardiology</i> , 2004, 19, 480-487.	0.8	17

#	ARTICLE	IF	CITATIONS
120	Antioxidant supplements for preventing gastrointestinal cancers. , 2004, , CD004183.		31
121	Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. <i>Journal of Hypertension</i> , 2004, 22, 2253-2261.	0.3	172
122	Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. <i>Journal of Hypertension</i> , 2004, 22, 1977-1982.	0.3	147
123	Epidemiology and treatment of the metabolic syndrome. <i>Annals of Medicine</i> , 2004, 36, 332-346.	1.5	91
125	Do we need to target prediabetic hypertensive patients?. <i>Journal of Hypertension</i> , 2005, 23, 2119-2125.	0.3	12
126	Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. <i>Journal of Hypertension</i> , 2005, 23, 463-473.	0.3	259
127	ãf;ã,ãfœãfãffã,ã,ãfãf%ãfãf1/4ãfãããšç¾ããèæãÿæ²-. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2005, 94,		40
128	The metabolic syndrome Modify root causes, treat risk factors. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2005, 18, 30-36.	0.1	3
129	Type 2 diabetes mellitus: a cardiovascular perspective. <i>International Journal of Clinical Practice</i> , 2005, 59, 798-816.	0.8	44
130	The accuracy of individual self-reported items to determine periodontal disease history. <i>European Journal of Oral Sciences</i> , 2005, 113, 135-140.	0.7	50
131	New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. <i>Current Problems in Cardiology</i> , 2005, 30, 241-279.	1.1	22
132	Metabolic and Vascular Abnormalities in Subjects at Risk for Type 2 Diabetes: The Early Start of a Dangerous Situation. <i>Archives of Medical Research</i> , 2005, 36, 241-249.	1.5	71
134	Heart Failure and its Treatment in Women. <i>Herz</i> , 2005, 30, 356-367.	0.4	40
135	Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. <i>Acta Diabetologica</i> , 2005, 42, s9-s16.	1.2	88
136	Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-Î³ system. <i>Current Hypertension Reports</i> , 2005, 7, 240-243.	1.5	27
137	Antihypertensive treatment and new-onset diabetes mellitus. <i>Current Hypertension Reports</i> , 2005, 7, 298-303.	1.5	18
138	Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice. <i>Current Hypertension Reports</i> , 2005, 7, 314-322.	1.5	22
139	Case-Based Study: From Prediabetes to Complicationsâ””Opportunities for Prevention. <i>PLoS Medicine</i> , 2005, 2, e40.	3.9	1



#	ARTICLE	IF	CITATIONS
140	Preventing Type 2 Diabetes Mellitus. <i>Journal of the American Board of Family Medicine</i> , 2005, 18, 37-43.	0.8	24
141	Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. <i>Circulation</i> , 2005, 112, 48-53.	1.6	211
143	Hypertension Genes Are Genetic Markers for Insulin Sensitivity and Resistance. <i>Hypertension</i> , 2005, 45, 799-803.	1.3	53
144	Impaired glucose tolerance and impaired fasting glucose "a review of diagnosis, clinical implications and management. <i>Diabetes and Vascular Disease Research</i> , 2005, 2, 9-15.	0.9	128
145	Retinal Arteriolar Narrowing, Hypertension, and Subsequent Risk of Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2005, 165, 1060.	4.3	124
146	Effects of Short-Term Glucocorticoids on Cardiovascular Biomarkers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3202-3208.	1.8	102
147	Deletion of the Angiotensin Type 2 Receptor (AT2R) Reduces Adipose Cell Size and Protects From Diet-Induced Obesity and Insulin Resistance. <i>Diabetes</i> , 2005, 54, 991-999.	0.3	183
149	A Noninferiority Comparison of Valsartan/Hydrochlorothiazide Combination Versus Amlodipine in Black Hypertensives. <i>Hypertension</i> , 2005, 46, 508-513.	1.3	35
150	PRIMARY PREVENTION OF DIABETES: What Can Be Done and How Much Can Be Prevented?. <i>Annual Review of Public Health</i> , 2005, 26, 445-467.	7.6	249
151	A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 736-744.	4.3	150
152	Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes. <i>Circulation</i> , 2005, 112, 1339-1346.	1.6	172
153	Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. <i>European Heart Journal</i> , 2005, 26, 2032-2038.	1.0	83
154	Ramipril in the treatment of vascular diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1911-1919.	0.9	5
155	The Prevention of Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 199-219.	1.2	53
156	Kidney and related chronic disease profiles and risk factors in three remote Australian Aboriginal communities. <i>Advances in Chronic Kidney Disease</i> , 2005, 12, 64-70.	0.6	21
157	Therapeutic Controversies in Hypertension. <i>Seminars in Nephrology</i> , 2005, 25, 227-235.	0.6	7
158	The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. <i>Cardiology Clinics</i> , 2005, 23, 165-183.	0.9	23
159	Hypertension and the Kidney. <i>Seminars in Nephrology</i> , 2005, 25, 236-245.	0.6	22

#	ARTICLE	IF	CITATIONS
160	The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 2261-2266.	4.3	198
161	The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2005, 65, 143-156.	0.6	55
162	Industry Pulse. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 53-56.	1.0	0
163	The Renin-Angiotensin System, Capri 2005. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 91-108.	1.0	0
164	Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. <i>Nature Clinical Practice Nephrology</i> , 2005, 1, 80-86.	2.0	293
165	Targeting vascular risk in patients with metabolic syndrome but without diabetes. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1065-1074.	1.5	66
166	MOREâ€”MOexipril and REgression of left ventricle hypertrophy in combination therapy. <i>International Journal of Cardiology</i> , 2005, 100, 199-206.	0.8	5
167	Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S2-S9.	1.1	41
168	Can type 2 diabetes mellitus be considered preventable?. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, S73-S81.	1.1	27
169	The D allele of the ACE I/D common gene variant is associated with Type 2 diabetes mellitus in Caucasian subjects. <i>Molecular Genetics and Metabolism</i> , 2005, 84, 83-89.	0.5	39
170	Long-term effectiveness of weight-loss interventions in adults with pre-diabetes. <i>American Journal of Preventive Medicine</i> , 2005, 28, 126-139.	1.6	123
171	Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm. <i>American Journal of Medicine</i> , 2005, 118, 939-947.	0.6	83
172	Long-term non-pharmacological weight loss interventions for adults with prediabetes. <i>The Cochrane Library</i> , 2005, , CD005270.	1.5	111
173	Angiotensin-Converting Enzyme Inhibitors. , 2005, , 669-682.		3
174	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	1.0	1,617
175	Recommendations for the Management of Intracranial Haemorrhage â€” Part I: Spontaneous Intracerebral Haemorrhage. <i>Cerebrovascular Diseases</i> , 2006, 22, 294-316.	0.8	393
176	Hypertension and Diabetes: Role of the Renin-Angiotensin System. <i>Endocrinology and Metabolism Clinics of North America</i> , 2006, 35, 469-490.	1.2	43
177	The Effect of Antihypertensive Agents on New-Onset Diabetes Mellitus. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 139-147.	1.0	19

#	ARTICLE	IF	CITATIONS
178	Effect of Ramipril on the Incidence of Diabetes. <i>New England Journal of Medicine</i> , 2006, 355, 1551-1562.	13.9	684
179	New Onset of Type 2 Diabetes Mellitus during Antihypertensive Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006, 13, 29-36.	1.0	1
180	Influencia de la prediabetes en el pronóstico cardiovascular del paciente hipertenso. <i>Hipertension</i> , 2006, 23, 86-92.	0.0	0
181	Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction. <i>Circulation</i> , 2006, 113, 1888-1904.	1.6	1,387
182	ACE Inhibitors and Angiotensin Receptor Antagonists and the Incidence of New-Onset Diabetes Mellitus. <i>Drugs</i> , 2006, 66, 1169-1177.	4.9	20
185	The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 957-961.	1.8	64
186	Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: Results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE). <i>American Heart Journal</i> , 2006, 152, 110-117.	1.2	39
187	The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. <i>Diabetes Research and Clinical Practice</i> , 2006, 74, 242-248.	1.1	16
188	Metabolic Syndrome and Prediabetes. <i>Disease-a-Month</i> , 2006, 52, 55-144.	0.4	17
189	Review Paper 1/2 CME. Insulin Resistance, Diabetes, Hypertension, and Renin-Angiotensin System Inhibition: Reducing Risk for Cardiovascular Disease. <i>Journal of Clinical Hypertension</i> , 2006, 8, 713-722.	1.0	35
190	The long-term effect of ramipril on Glut2-protein and Protein Tyrosine Phosphatase 1B in an animal model of type 2 diabetes (OLETF rat). <i>The Journal of Korean Diabetes Association</i> , 2006, 30, 25.	0.1	0
191	Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials. <i>Current Clinical Pharmacology</i> , 2006, 1, 21-33.	0.2	5
193	Prevention of Progression in Diabetic Nephropathy. <i>Diabetes Spectrum</i> , 2006, 19, 18-24.	0.4	29
194	The tissue renin-angiotensin system and intracellular signalling. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 8-13.	1.0	57
195	Hemodynamic and metabolic responses to interstitial angiotensin II in normal weight and obese men. <i>Journal of Hypertension</i> , 2006, 24, 1165-1171.	0.3	8
196	Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>Journal of Hypertension</i> , 2006, 24, S3-S7.	0.3	13
197	The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 365-380.	2.2	9
198	Anti-diabetic effect of blockade of the renin-angiotensin system. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 396-403.	2.2	26

#	ARTICLE	IF	CITATIONS
199	Preventive medicine beyond 65. <i>Geriatrics and Gerontology International</i> , 2006, 6, 73-81.	0.7	5
200	RAS inhibition in hypertension. <i>Journal of Human Hypertension</i> , 2006, 20, 101-108.	1.0	97
203	Obesity, diabetes, and associated risk factors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 67-78.	0.4	6
204	Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. <i>Current Diabetes Reports</i> , 2006, 6, 47-54.	1.7	70
205	Inflammation and the metabolic syndrome: Role of angiotensin II and oxidative stress. <i>Current Hypertension Reports</i> , 2006, 8, 191-198.	1.5	89
206	Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the International Verapamil SR-Trandolapril Study) <i>Tj ETQq1 1 0.784314 rgBT / Overlock</i>	1.4	6
208	Dislipemia diab�tica, s�ndrome metab�lico y riesgo cardiovascular. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006, 6, 13G-23G.	0.2	0
209	Insulin Resistance and Cardiovascular Risk: New Insights From Molecular and Cellular Biology. <i>Trends in Cardiovascular Medicine</i> , 2006, 16, 183-188.	2.3	53
210	New and Emerging Strategies for Reducing Cardiometabolic Risk Factors. <i>Pharmacotherapy</i> , 2006, 26, 13S-31S.	1.2	9
211	Evaluating and Treating Cardiometabolic Risk Factors: A Case Discussion. <i>Pharmacotherapy</i> , 2006, 26, 32S-41S.	1.2	0
212	The Metabolic Syndrome and Cardiometabolic Risk: Scope of the Problem and Current Standard of Care. <i>Pharmacotherapy</i> , 2006, 26, 3S-12S.	1.2	16
213	Differing Effects of Antihypertensive Drugs on the Incidence of Diabetes Mellitus Among Patients With Hypertensive Kidney Disease. <i>Archives of Internal Medicine</i> , 2006, 166, 797.	4.3	34
214	Elevated Markers of Endothelial Dysfunction Predict Type 2 Diabetes Mellitus in Middle-Aged Men and Women From the General Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 398-405.	1.1	140
215	Quinapril Treatment Increases Insulin-Stimulated Endothelial Function and Adiponectin Gene Expression in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1001-1008.	1.8	62
216	Of Hopes and DREAMS: The Quest to Prevent Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4762-4763.	1.8	1
219	Therapeutic potential of angiotensin receptor blockers in hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 625-635.	1.9	6
220	Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H2021-H2025.	1.5	44
221	The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, 243-246.	1.0	28

#	ARTICLE	IF	CITATIONS
222	Loss of Nocturnal Blood Pressure Fall in Patients With Renal Impairment. Archives of Internal Medicine, 2006, 166, 2158.	4.3	3
223	Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment. Archives of Internal Medicine, 2006, 166, 2191.	4.3	243
224	Diabetes mellitus in older men. Aging Male, 2006, 9, 139-147.	0.9	35
225	"Anti-Inflammatory" Drugs and Their Effects on Type 2 Diabetes. Diabetes Technology and Therapeutics, 2006, 8, 18-27.	2.4	41
226	Hemostatic Markers of Endothelial Dysfunction and Risk of Incident Type 2 Diabetes: The Framingham Offspring Study. Diabetes, 2006, 55, 530-537.	0.3	162
227	Signaling by the Angiotensin-Converting Enzyme. Circulation Research, 2006, 98, 887-896.	2.0	157
228	Treating the metabolic syndrome. Expert Review of Cardiovascular Therapy, 2007, 5, 491-506.	0.6	53
229	Candesartan: from left ventricular hypertrophy to heart failure, a global approach. Expert Review of Cardiovascular Therapy, 2007, 5, 825-834.	0.6	2
230	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opinion on Therapeutic Targets, 2007, 11, 191-205.	1.5	24
231	Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrology Dialysis Transplantation, 2007, 22, 1943-1949.	0.4	36
233	In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients. Hypertension, 2007, 50, 984-990.	1.3	49
234	Diabetes prevention between the HOPE and the DREAM. Therapy: Open Access in Clinical Medicine, 2007, 4, 1-4.	0.2	6
235	Reducing diabetes incidence through the inhibition of the renin-angiotensin system: a strategy for reducing cardiovascular mortality and morbidity?. Journal of Cardiovascular Medicine, 2007, 8, 473-482.	0.6	3
236	Effect of Ramipril on the Incidence of Diabetes. Yearbook of Endocrinology, 2007, 2007, 4-6.	0.0	0
237	Changing horizons: approaches to diabetes care, current and future. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 95-97.	1.2	1
238	Effect of Ramipril on the Incidence of Diabetes. Yearbook of Cardiology, 2007, 2007, 79-81.	0.0	0
239	Differing Effects of Antihypertensive Drugs on the Incidence of Diabetes Mellitus Among Patients With Hypertensive Kidney Disease. Yearbook of Cardiology, 2007, 2007, 82-84.	0.0	0
240	Development and bioavailability assessment of ramipril nanoemulsion formulation. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 66, 227-243.	2.0	567

#	ARTICLE	IF	CITATIONS
241	Renin-angiotensin-system blockade in the prevention of diabetes. <i>Diabetes Research and Clinical Practice</i> , 2007, 76, S13-S21.	1.1	28
242	Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. <i>Lancet</i> , The, 2007, 369, 201-207.	6.3	936
243	Beneficios adicionales del tratamiento con candesartán en la insuficiencia cardíaca. Programa CHARM. <i>Hipertension</i> , 2007, 24, 34-42.	0.0	0
244	2007 ESH-ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2007, 16, 135-232.	0.7	292
245	Therapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 201-211.	0.6	4
246	Prevention of Diabetes Development in Those with the Metabolic Syndrome. <i>Medical Clinics of North America</i> , 2007, 91, 1091-1105.	1.1	4
248	Insulin signaling in hypertension. <i>International Congress Series</i> , 2007, 1303, 41-47.	0.2	2
249	Influenza Viruses in Animal Wildlife Populations. <i>Current Topics in Microbiology and Immunology</i> , 2007, 315, 67-83.	0.7	47
250	Overviews of Pathogen Emergence: Which Pathogens Emerge, When and Why?. <i>Current Topics in Microbiology and Immunology</i> , 2007, 315, 85-111.	0.7	114
251	Management of hypertension in diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 341-357.	1.2	0
252	Angiotensin-Converting Enzyme Inhibitors. , 2007, , 985-1001.		0
253	The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type 2 diabetes mellitus. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 979-987.	0.9	17
254	Differential effect of $\beta$ -blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. <i>Diabetic Medicine</i> , 2007, 24, 759-763.	1.2	29
255	Effect of angiotensin II receptor blockers on insulin resistance in maintenance haemodialysis patients. <i>Nephrology</i> , 2007, 12, 342-347.	0.7	10
256	Endothelial dysfunction in insulin resistance and type 2 diabetes. <i>Journal of Internal Medicine</i> , 2007, 262, 173-183.	2.7	148
257	The importance of $\beta$ -cell management in type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2007, 61, 10-19.	0.8	29
258	Prevention of Stroke in Patients with Hypertension. <i>American Journal of Cardiology</i> , 2007, 100, S17-S24.	0.7	59
259	Diabetes Prevention Between RAAS Inhibition and PPAR-Gamma Stimulation: The Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Trial. <i>Journal of the Cardiometabolic Syndrome</i> , 2007, 2, 149-150.	1.7	6

#	ARTICLE	IF	CITATIONS
262	The renin-angiotensin system and insulin resistance. <i>Current Diabetes Reports</i> , 2007, 7, 34-42.	1.7	50
263	Prevention of type 2 diabetes: An update. <i>Current Diabetes Reports</i> , 2007, 7, 200-207.	1.7	10
265	Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. <i>Endocrine</i> , 2008, 34, 56-61.	1.1	92
266	Enhanced Stability of Ramipril in Nanoemulsion Containing Cremophor-EL: A Technical Note. <i>AAPS PharmSciTech</i> , 2008, 9, 1097-1101.	1.5	39
267	Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. , 2008, , CD007176.		197
268	BMI and Lipid Levels in Mexican American Children Diagnosed with Type 2 Diabetes. <i>Worldviews on Evidence-Based Nursing</i> , 2008, 5, 142-147.	1.2	6
269	Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. <i>International Journal of Clinical Practice</i> , 2008, 62, 1087-1095.	0.8	116
270	Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes. <i>Vascular Pharmacology</i> , 2008, 48, 47-53.	1.0	22
271	Type 2 Diabetes Mellitus and Heart Failure. <i>Pharmacotherapy</i> , 2008, 28, 170-192.	1.2	29
272	Effects of Angiotensinâ€Converting Enzyme Inhibitor Therapy on Levels of Inflammatory Markers in Response to Exerciseâ€Induced Stress: Studies in the Metabolic Syndrome. <i>Journal of the Cardiometabolic Syndrome</i> , 2008, 3, 12-17.	1.7	6
273	The Metabolic Syndrome and Cardiovascular Disease: Part 2. <i>Preventive Cardiology</i> , 2008, 11, 223-229.	1.1	24
274	Clinical Characteristics and Outcomes in Hypertensive Patients of Hispanic Descent. <i>Preventive Cardiology</i> , 2008, 11, 116-120.	1.1	9
275	Management of Cardiometabolic Syndrome in the Primary and Secondary Prevention of Cardiovascular Disease. <i>Journal for Nurse Practitioners</i> , 2008, 4, 673-680.	0.4	2
276	Efficacy of folic acid and enalapril combined therapy on reduction of blood pressure and plasma glucose: A multicenter, randomized, double-blind, parallel-controlled, clinical trial. <i>Nutrition</i> , 2008, 24, 1088-1096.	1.1	23
277	Protection of pancreatic beta-cells: Is it feasible?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 74-83.	1.1	71
278	Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association. <i>Journal of Cardiac Failure</i> , 2008, 14, 615-625.	0.7	81
279	Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1093-1100.	1.5	24
280	Efecto de 3 modelos de dieta en la respuesta de glucosa e insulina, perfil lipÃdico y funciÃn endotelial en individuos con resistencia a la insulina. <i>ClÃnica E InvestigaciÃn En Arteriosclerosis</i> , 2008, 20, 55-63.	0.4	1

#	ARTICLE	IF	CITATIONS
282	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. <i>Lancet</i> , The, 2008, 372, 1174-1183.	6.3	896
283	The prevention of type 2 diabetes. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 382-393.	2.9	216
284	A Practical "ABCDE" Approach to the Metabolic Syndrome. <i>Mayo Clinic Proceedings</i> , 2008, 83, 932-943.	1.4	42
285	Blood Viscosity and Hematocrit as Risk Factors for Type 2 Diabetes Mellitus: The Atherosclerosis Risk in Communities (ARIC) Study. <i>American Journal of Epidemiology</i> , 2008, 168, 1153-1160.	1.6	164
286	Antioxidant supplements for preventing gastrointestinal cancers. <i>The Cochrane Library</i> , 2008, , CD004183.	1.5	109
287	Hypertension and Diabetes. , 2008, 45, 82-106.		48
288	Lewis K. Dahl Memorial Lecture. <i>Hypertension</i> , 2008, 52, 37-43.	1.3	36
289	Pathogenesis, Risk Assessment and Prevention of Type 2 Diabetes mellitus. <i>Obesity Facts</i> , 2008, 1, 128-137.	1.6	24
290	Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 289-303.	0.6	11
291	Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 935-940.	0.5	16
292	Hydrochlorothiazide, but not Candesartan, Aggravates Insulin Resistance and Causes Visceral and Hepatic Fat Accumulation. <i>Hypertension</i> , 2008, 52, 1030-1037.	1.3	115
293	Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2008, 5, 59-66.	0.9	38
294	Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2008, 359, 1225-1237.	13.9	703
295	Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension. <i>Diabetes Care</i> , 2008, 31, 353-360.	4.3	110
296	Beyond the classic angiotensin-receptor-blocker profile. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, S19-S26.	3.3	30
297	A Practical "ABCDE" Approach to the Metabolic Syndrome. <i>Mayo Clinic Proceedings</i> , 2008, 83, 932-943.	1.4	73
298	Type-2 diabetes and endothelial dysfunction: exploring the road to disease in the reverse direction. <i>Journal of Hypertension</i> , 2008, 26, 2096-2100.	0.3	2
300	Benefits of ACE Inhibitors in Diabetes. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2027.	0.1	8



#	ARTICLE	IF	CITATIONS
301	Vascular and metabolic effects of angiotensin II receptor blockers. Expert Opinion on Pharmacotherapy, 2009, 10, 173-189.	0.9	18
302	Aldosterone Inhibits Insulin-Induced Glucose Uptake by Degradation of Insulin Receptor Substrate (IRS) 1 and IRS2 via a Reactive Oxygen Species-Mediated Pathway in 3T3-L1 Adipocytes. Endocrinology, 2009, 150, 1662-1669.	1.4	107
303	Are Renin-Angiotensin-Aldosterone System Blockers Distinguishable Based on Cardiovascular and Renal Outcomes in Nephropathy?. Postgraduate Medicine, 2009, 121, 77-88.	0.9	6
304	Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model. Hypertension Research, 2009, 32, 617-624.	1.5	11
305	A Selective Peroxisome Proliferator-Activated Receptor- $\beta$ Modulator, Telmisartan, Binds to the Receptor in a Different Fashion from Thiazolidinediones. Endocrinology, 2009, 150, 862-870.	1.4	30
306	Cardiac cachexia: A systematic overview. , 2009, 121, 227-252.		297
307	Update on the metabolic syndrome: Hypertension. Current Hypertension Reports, 2009, 11, 150-155.	1.5	18
308	Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. Advances in Therapy, 2009, 26, 313-24.	1.3	13
309	Possible contribution of the non- $\alpha$ -proteolytic activation of prorenin to the development of insulin resistance in fructose-fed rats. Experimental Physiology, 2009, 94, 1016-1023.	0.9	41
310	Risk factor assessment for new onset diabetes: literature review. Diabetes, Obesity and Metabolism, 2009, 11, 177-187.	2.2	31
311	The sweeter side of ACE2: Physiological evidence for a role in diabetes. Molecular and Cellular Endocrinology, 2009, 302, 193-202.	1.6	183
312	The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative Stress. Medical Clinics of North America, 2009, 93, 569-582.	1.1	144
313	A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient. American Journal of Cardiovascular Drugs, 2009, 9, 149-162.	1.0	8
314	Glucose and Non-glucose Predictors of Future Onset of Type 2 Diabetes in Newly Diagnosed Essential Hypertensives. Journal of the Chinese Medical Association, 2009, 72, 564-572.	0.6	0
315	Renin-angiotensin system activation in renal adipogenesis. American Journal of Physiology - Renal Physiology, 2010, 298, F391-F400.	1.3	15
316	Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile. Journal of Nutrition, Health and Aging, 2010, 14, 457-460.	1.5	29
317	The Role of Renin-Angiotensin Agents in Altering the Natural History of Type 2 Diabetes Mellitus. Current Cardiology Reports, 2010, 12, 464-471.	1.3	15
318	Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity. Current Diabetes Reports, 2010, 10, 139-144.	1.7	25

#	ARTICLE	IF	CITATIONS
319	Renin-Ângiotensin System Blockade and Cardiovascular and Renal Protection. American Journal of Cardiology, 2010, 105, 30A-35A.	0.7	88
320	Half full, half empty, or negative? Results of recent clinical trials. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2010, 27, 174-175.	0.2	0
321	Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diabetes, Obesity and Metabolism, 2010, 12, 267-287.	2.2	76
322	Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clinical Interventions in Aging, 2010, 5, 403.	1.3	19
323	Evidence for the Importance of Adiponectin in the Cardioprotective Effects of Pioglitazone. Hypertension, 2010, 55, 69-75.	1.3	46
324	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1477-1490.	13.9	588
325	Tissue-specific effects of valsartan on <i>rs1344706</i> and <i>fiaf</i> gene expression in the <i>ob/ob</i> mouse. Diabetes and Vascular Disease Research, 2010, 7, 231-238.	0.9	6
326	Endothelial Dysfunction, Inflammation, and Apoptosis in Diabetes Mellitus. Mediators of Inflammation, 2010, 2010, 1-15.	1.4	270
328	Risk Factors and Outcomes Associated With Posttransplant Diabetes Mellitus in Kidney Transplant Recipients. Transplantation Proceedings, 2010, 42, 1685-1689.	0.3	28
329	On the local cardiac renin angiotensin system. Basic and clinical implications. Peptides, 2011, 32, 1774-1779.	1.2	62
330	Prevalencia de la diabetes mellitus 2. Semergen, 2011, 37, 496-503.	0.2	1
331	Mechanistic and Clinical Aspects of Renin-Angiotensin-Aldosterone System Blockade in the Prevention of Diabetes Mellitus and Cardiovascular Disease. Endocrine Practice, 2011, 17, 430-440.	1.1	14
332	Endothelial Dysfunction and Therapeutic Intervention in Type 2 Diabetes. , 0, , .		0
333	Alterations in Nutrition and Body Mass in Heart Failure. , 2011, , 330-345.		0
334	Telmisartan and cardioprotection. Vascular Health and Risk Management, 2011, 7, 677.	1.0	9
335	Ramipril modulates circadian gene expression in skeletal muscle. Pharmacogenetics and Genomics, 2011, 21, 751-759.	0.7	4
337	Review article: pancreatic renin-angiotensin systems in health and disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 840-852.	1.9	40
338	Opposing Effects of $\beta$ Blockers and Angiotensin-Converting Enzyme Inhibitors on Development of New-Onset Diabetes Mellitus in Patients With Stable Coronary Artery Disease. American Journal of Cardiology, 2011, 107, 1705-1709.	0.7	15

#	ARTICLE	IF	CITATIONS
339	Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM). <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 653-661.	0.8	26
340	Update on the Prevention of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2011, 11, 56-63.	1.7	21
341	Should the Metabolic Syndrome Patient with Prediabetes Be Offered Pharmacotherapy?. <i>Current Diabetes Reports</i> , 2011, 11, 91-98.	1.7	11
342	Pharmacological and non-pharmacological interventions to influence adipose tissue function. <i>Cardiovascular Diabetology</i> , 2011, 10, 13.	2.7	43
343	Drug therapy for the prevention of type 2 diabetes – is there a medical rationale?. <i>British Journal of Diabetes and Vascular Disease</i> , 2011, 11, 168-174.	0.6	4
344	Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials. <i>American Journal of Hypertension</i> , 2011, 24, 582-590.	1.0	78
345	The association between circulating angiotensin-converting enzyme and cardiovascular risk in the elderly: a cross-sectional study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 281-289.	1.0	22
346	Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes. <i>Diabetes Care</i> , 2011, 34, 1902-1907.	4.3	27
347	Comparison Between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients With Glucose Intolerance. <i>Hypertension</i> , 2012, 59, 580-586.	1.3	44
348	Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. <i>European Journal of Pharmacology</i> , 2012, 697, 1-12.	1.7	76
349	Relationship between Telmisartan Dose and Glycaemic Control in Japanese Patients with Type 2 Diabetes Mellitus and Hypertension. <i>Clinical Drug Investigation</i> , 2012, 32, 577-582.	1.1	2
351	Prevention of Type 2 Diabetes: Evidence from Clinical Trials. , 2012, , 143-160.		0
352	Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. <i>The Cochrane Library</i> , 2012, 2012, CD007176.	1.5	479
353	Role of Lipotoxicity in Endothelial Dysfunction. <i>Heart Failure Clinics</i> , 2012, 8, 589-607.	1.0	94
355	Myocardial Insulin Resistance: An Overview of Its Causes, Effects, and Potential Therapy. , 0, , .		6
356	The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H1219-H1230.	1.5	200
357	Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. <i>Heart Failure Reviews</i> , 2012, 17, 325-344.	1.7	287
358	The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. <i>Obesity Reviews</i> , 2012, 13, 136-149.	3.1	219

#	ARTICLE	IF	CITATIONS
359	Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. <i>Cardiovascular Diabetology</i> , 2012, 11, 1.	2.7	59
360	Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: A meta-analysis of 72,128 patients. <i>International Journal of Cardiology</i> , 2013, 167, 2605-2610.	0.8	18
361	Angiotensin-converting enzyme 2, angiotensin-(1 $\alpha$ -7) and Mas: new players of the renin $\alpha$ -angiotensin system. <i>Journal of Endocrinology</i> , 2013, 216, R1-R17.	1.2	414
362	Angiotensin-(1 $\alpha$ -7): beyond the cardio-renal actions. <i>Clinical Science</i> , 2013, 124, 443-456.	1.8	185
363	Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. <i>Journal of Translational Medicine</i> , 2013, 11, 12.	1.8	4
364	Antihypertensive treatment in diabetic patients. Review of current data. <i>Maturitas</i> , 2013, 75, 142-147.	1.0	2
365	Acute regulation of pancreatic islet microcirculation and glycaemia by telmisartan and ramipril: discordant effects between normal and Type 2 diabetic rats. <i>Clinical Science</i> , 2013, 125, 433-438.	1.8	4
366	Sympathoexcitation Associated with Renin-Angiotensin System in Metabolic Syndrome. <i>International Journal of Hypertension</i> , 2013, 2013, 1-7.	0.5	21
367	Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 697-705.	0.7	12
368	Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. <i>Pharmacogenomics Journal</i> , 2013, 13, 430-436.	0.9	18
369	Are we overtreating cardiovascular disease in diabetic patients?. <i>Diabetes Management</i> , 2013, 3, 271-275.	0.5	0
370	Pharmacological approach to cardiovascular risk in metabolic syndrome. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 403-409.	0.6	5
371	Role of Ace Inhibitors In Atherosclerosis. <i>International Journal of Biomedical and Advance Research</i> , 2013, 4, 849.	0.1	2
372	Serum potassium is an age-dependent risk factor for pre-diabetes and diabetes in the Israeli population. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 103-109.	0.9	6
373	Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. <i>Clinical Science</i> , 2014, 126, 471-482.	1.8	72
374	Associations of genetic polymorphisms in the renin-angiotensin system with central aortic and ambulatory blood pressure in type 2 diabetic patients. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2014, 15, 61-68.	1.0	3
375	Misclassification in assessment of diabetogenic risk using electronic health records. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 875-881.	0.9	7
376	Changes in inflammatory markers after sleeve gastrectomy in patients with impaired glucose homeostasis and type 2 diabetes. <i>Surgery for Obesity and Related Diseases</i> , 2014, 10, 1123-1128.	1.0	45

#	ARTICLE	IF	CITATIONS
377	The Glycemic Effects of Antihypertensive Medications. <i>Current Hypertension Reports</i> , 2014, 16, 410.	1.5	14
378	Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, 142, 375-415.		437
379	The effect of RAAS blockade on the progression of diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2014, 10, 77-87.	4.1	128
381	Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 719-727.	2.2	124
382	Milk-derived peptide Val-Pro-Pro (VPP) inhibits obesity-induced adipose inflammation via an angiotensin-converting enzyme (ACE) dependent cascade. <i>Molecular Nutrition and Food Research</i> , 2015, 59, 2502-2510.	1.5	43
383	Clinical Trials on Diabetes Mellitus. , 0, , .		2
384	Hypertension and Dyslipidemia in Patients with Pre-Diabetes. , 2015, , 157-179.		1
385	Azelidipine and glucose tolerance: possible indications and treatment selection for hypertensive patients with metabolic disorders. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 23-31.	0.6	6
386	Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study. <i>European Journal of Endocrinology</i> , 2015, 172, 11-20.	1.9	85
388	ACE2 deficiency reduces $\beta^2$ -cell mass and impairs $\beta^2$ -cell proliferation in obese C57BL/6 mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E621-E631.	1.8	60
389	Primary prevention of diabetes mellitus: current strategies and future trends. <i>Italian Journal of Medicine</i> , 0, 10, .	0.2	0
390	Inactivation of adipose angiotensinogen reduces adipose tissue macrophages and increases metabolic activity. <i>Obesity</i> , 2016, 24, 359-367.	1.5	28
392	Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2016, 59, 255-265.	2.9	51
394	Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1742-1750.	1.6	15
395	Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene?. <i>Value in Health Regional Issues</i> , 2017, 12, 90-98.	0.5	5
396	The serum protein responses to treatment with XiaoKe Pill and Glibenclamide in type 2 diabetes patients. <i>Clinical Proteomics</i> , 2017, 14, 19.	1.1	8
397	A bioluminescence resonance energy transfer 2 (BRET2) assay for monitoring seven transmembrane receptor and insulin receptor crosstalk. <i>Journal of Receptor and Signal Transduction Research</i> , 2017, 37, 590-599.	1.3	3
398	Dietary Fat Intake Modulates Effects of a Frequent ACE Gene Variant on Glucose Tolerance with association to Type 2 Diabetes. <i>Scientific Reports</i> , 2017, 7, 9234.	1.6	12

#	ARTICLE	IF	CITATIONS
399	Association of angiotensin-II levels with albuminuria in subjects with normal glucose metabolism, prediabetes, and type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1499-1505.	1.2	10
400	From Sea to Shining Sea and the Great Plains to Patagonia: A Review on Current Knowledge of Diabetes Mellitus in Hispanics/Latinos in the US and Latin America. <i>Frontiers in Endocrinology</i> , 2017, 8, 298.	1.5	27
401	Egg White Ovotransferrin-Derived ACE Inhibitory Peptide Ameliorates Angiotensin II-Stimulated Insulin Resistance in Skeletal Muscle Cells. <i>Molecular Nutrition and Food Research</i> , 2018, 62, 1700602.	1.5	35
402	Prevention of Type 2 Diabetes. <i>Endocrinology</i> , 2018, , 1-20.	0.1	2
403	Relationship between self-assessment and clinical evaluation of dental plaque and gingival condition in Japanese adolescents. <i>International Journal of Dental Hygiene</i> , 2018, 16, 144-150.	0.8	4
404	[Sar1, Ile4, Ile8]-Angiotensin II Potentiates Insulin Receptor Signalling and Glycogen Synthesis in Hepatocytes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 460-469.	1.2	2
405	The Renin-Angiotensin-Aldosterone System and the Kidney. , 2018, , 27-41.		3
406	Independent Association of Serum Aldosterone Level with Metabolic Syndrome and Insulin Resistance in Korean Adults. <i>Korean Circulation Journal</i> , 2018, 48, 198.	0.7	15
407	Medications that cause weight gain and alternatives in Canada: a narrative review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 427-438.	1.1	57
408	Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3986-3995.	1.8	3
409	The relationship between glucose variability and insulin sensitivity and oxidative stress in subjects with prediabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 158, 107911.	1.1	23
410	Comparative risk of new-onset diabetes mellitus for antihypertensive drugs in elderly: A Bayesian network meta-analysis. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1082-1090.	1.0	4
411	Pancreatic AT1aR Deficiency Decreases Insulin Secretion in Obese C57BL/6 Mice. <i>American Journal of Hypertension</i> , 2019, 32, 597-604.	1.0	3
412	Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 154.	1.7	6
413	The Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive Medications for Incident Glucose-level Elevation. <i>American Journal of Hypertension</i> , 2019, 32, 343-349.	1.0	0
414	Insulin Resistance the Hinge Between Hypertension and Type 2 Diabetes. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 515-526.	1.0	89
415	Angiotensin converting enzyme inhibitor potentiates the hypoglycaemic effect of NG-nitro-L-arginine methyl ester (L-NAME) in rats. <i>Archives of Physiology and Biochemistry</i> , 2020, , 1-9.	1.0	0
416	Renin Angiotensin Aldosterone System, Glucose Homeostasis, and Prevention of Type 2 Diabetes: Mechanistic Insights and Evidence from Major Clinical Trials. , 0, , .		1

#	ARTICLE	IF	CITATIONS
417	Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives. International Journal of Molecular Sciences, 2021, 22, 775.	1.8	25
418	Pharmacological Prevention of Type 2 Diabetes. , 0, , 449-474.		1
419	Controversies in Treating Diabetes. , 2008, , .		3
421	The Sympatho-Adrenal System in the Metabolic Syndrome. , 2008, , 85-104.		3
422	The Metabolic Syndrome. , 2010, , 822-839.		2
423	The secondary prevention of cardiovascular disease. , 2005, , 769-791.		1
424	Diabetes Mellitus and Metabolic Syndrome. , 2009, , 465-496.		5
425	Egg white hydrolysate shows insulin mimetic and sensitizing effects in 3T3-F442A pre-adipocytes. PLoS ONE, 2017, 12, e0185653.	1.1	32
426	Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk. Current Pharmaceutical Design, 2013, 19, 2420-2431.	0.9	37
427	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes Care, 2020, 43, 835-842.	4.3	28
428	Obesity and Hypertension. Fundamental and Clinical Cardiology, 2006, , 33-50.	0.0	1
430	A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.. Cleveland Clinic Journal of Medicine, 2002, 69, 985-989.	0.6	22
431	Metabolic syndrome and the hepatorenal reflex. , 2016, 7, 83.		4
432	Metabolic syndrome and the hepatorenal reflex. , 2016, 7, 99.		6
433	Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. Oman Medical Journal, 2012, 27, 27-30.	0.3	7
434	Short-Term Calorie Restriction in Early Life Attenuates the Development of Proteinuria but Not Glucose Intolerance in Type 2 Diabetic OLETF Rats. Isrn Endocrinology, 2011, 2011, 1-7.	2.0	8
435	Trials That Matter: Rosiglitazone, Ramipril, and the Prevention of Type 2 Diabetes. Annals of Internal Medicine, 2007, 146, 461.	2.0	14
436	Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension, 2021, 78, 1197-1205.	1.3	85

#	ARTICLE	IF	CITATIONS
437	The 2000sâ€”decade of prevention. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 127-129.	0.6	1
440	Is Prevention the Solution to the Worldwide Epidemic Explosion of Type 2 Diabetes Mellitus?. European Endocrinology, 2006, , 19.	0.8	0
442	Overview of diabetes mellitus. , 2007, , 1-16.		0
443	Prevention of Type 2 Diabetes Mellitus. Endocrine Practice, 2007, 13, 13-16.	1.1	1
444	A new page in hypertension management in diabetes mellitus type 2. ADVANCE study first results. Arterial Hypertension (Russian Federation), 2007, 13, 212-219.	0.1	1
445	Insulin Action and Endothelial Function. , 2008, , 107-135.		1
446	The Role of Obesity in Insulin Resistance. , 2008, , 37-55.		0
447	The Reninâ€”Angiotensinâ€”Aldosterone System and the Kidney. , 2008, , 167-180.		0
448	Clinical Management of the Metabolic Syndrome. , 2008, , 154-223.		2
449	The changing strategies of antihypertensive treatment in metabolic syndrome: From drugs of choice towards an optimal therapeutic combination. Arterial Hypertension (Russian Federation), 2008, 14, 65-70.	0.1	0
450	Prevention of Type 2 Diabetes. , 2009, , 55-62.		0
452	Ramipril therapy in the framework of evidence-based medicine. Arterial Hypertension (Russian) Tj ETQq1 1 0.784314 rgBT / Overlock 10	0.1	0
453	Cardiac Cachexia in Chronic Heart Failure: The Metabolic Facet of CHF. , 2010, , 165-185.		2
457	The Pre-Diabetic, Insulin-Resistant State. , 2012, , 433-452.		0
459	Relationship between Telmisartan Dose and Glycaemic Control in Japanese Patients with Type 2 Diabetes Mellitus and Hypertension. Clinical Drug Investigation, 2012, 32, 577-582.	1.1	0
460	The Glycemic Consequences of Antihypertensive Medications. , 2015, , 935-948.		0
461	Prevention of Type 2 Diabetes. Endocrinology, 2018, , 465-484.	0.1	0
462	The place of ramipril in modern guidelines for the management of patients with cardiovascular diseases. Meditsinskiy Sovet, 2019, , 34-41.	0.1	3



#	ARTICLE	IF	CITATIONS
463	The Effects of Valsartan on Cardiac Function and Pro-Oxidative Parameters in the Streptozotocin-Induced Diabetic Rat Heart. Serbian Journal of Experimental and Clinical Research, 2020, 21, 247-256.	0.2	1
464	Prevention of Type 2 Diabetes. Cardiovascular Prevention and Pharmacotherapy, 2020, 2, 63.	0.0	0
465	Hypertonie. , 2005, , 377-396.		0
466	The Renin-Angiotensin System in Pancreatic Stellate Cells: Implications in the Development and Progression of Type 2 Diabetes Mellitus. , 2007, , 73-86.		0
467	Assessment of the Role of ACE Inhibitors in the Elderly. , 2005, , 321-348.		0
468	Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. , 2006, , 113-143.		0
469	Therapies for Delay or Prevention of Type 2 Diabetes. , 2008, , 85-96.		1
470	Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vascular Health and Risk Management, 2007, 3, 937-45.	1.0	22
471	Endothelial dysfunction in diabetes mellitus. Vascular Health and Risk Management, 2007, 3, 853-76.	1.0	325
472	The renin-angiotensin system and diabetes: an update. Vascular Health and Risk Management, 2008, 4, 787-803.	1.0	107
473	Standards of Medical Care in Diabetesâ€“2006. Diabetes Care, 2006, 29, s4-s42.	4.3	702
474	SIT1 transporter as a potential novel target in treatment of COVID-19. Biomolecular Concepts, 2021, 12, 156-163.	1.0	7
475	Glucose Abnormalities and Cardiovascular Disease:â€œDysglycemiaâ€œas an Emerging Cardiovascular Risk Factor. , 0, , 161-169.		0
476	Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Failure Reviews, 2023, 28, 585-596.	1.7	11
480	Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective. Swiss Medical Weekly, 0, , .	0.8	7
481	Prevalence and risk factors associated with prediabetes and undiagnosed diabetes in France: The national CONSTANCES cohort. Diabetes Epidemiology and Management, 2023, 10, 100121.	0.4	3
482	Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials. BMC Medicine, 2022, 20, .	2.3	2
483	Diabetogenic Effects of Antihypertensive Drugs and Statins. Updates in Hypertension and Cardiovascular Protection, 2023, , 421-435.	0.1	0

#	ARTICLE	IF	CITATIONS
486	Role of newer anti-diabetes drugs in prediabetes: A systematic review. , 2024, , 393-406.		0